Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Multiple Dose Regimens of MT-3724 for the Treatment of Patients With Relapsed Chronic B-cell Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Trial Profile

Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Multiple Dose Regimens of MT-3724 for the Treatment of Patients With Relapsed Chronic B-cell Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 04 Mar 2016

At a glance

  • Drugs MT 3724 (Primary)
  • Indications B cell lymphoma; Leukaemia
  • Focus Adverse reactions
  • Sponsors Molecular Templates
  • Most Recent Events

    • 29 Feb 2016 Status changed from not yet recruiting to withdrawn prior to enrolment as reported by ClinicalTrials.gov.
    • 24 Sep 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top